MBRX

Maxim Group analyst Jason McCarthy maintained a Buy rating on Moleculin Biotech (MBRX - Research Report) yesterday and set a price target of $5.00. The company's shares opened today at $1.81.McCarthy covers the Healthcare sector, focusing on stocks such as Atossa Therapeutics, Capricor Therapeutics, and VistaGen Therapeutics. According to TipRanks, McCarthy has an average return of -36.4% and a 19.32% success rate on recommended stocks. Moleculin Biotech has an analyst consensus of Moderate Buy, with a price target consensus of $9.50.See the top stocks recommended by analysts >>The company has a one-year high of $3.20 and a one-year low of $1.02. Currently, Moleculin Biotech has an average volume of 52.07K.
https://www.tipranks.com/news/blurbs/maxim-group-keeps-their-buy-rating-on-moleculin-biotech-mbrx-2?utm_source=advfn.com&utm_medium=referral